Govindhan Thiruppathi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Govindhan Thiruppathi has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Adarsha Mahendra Upadhyay
Department of Gastrointestinal Surgery, School of Overseas Education, Guizhou Medical University, Guiyang 550025, China
2 shared publications - Arvind Kumar Shukla
School of Biomedical Convergence Engineering, Pusan National University, Yangsan 50612, Republic of Korea
2 shared publications - Raj Kumar Mongre
Department of Surgery, Boston Children’s Hospital, Harvard Medical School, Harvard University, 300 Longwood Ave, Boston, MA 02115, USA
2 shared publications - Sandhya Shukla
Department of Pharmacology, Bharti Vidyapeeth Deemed University Medical College, Pune 411043, India
2 shared publications - Sayan Deb Dutta
Department of Biosystems Engineering, Kangwon National University, Chuncheon-si 24341, Gangwon-do, Republic of Korea
2 shared publications - Chandra Dhar Shukla
Department of Pharmacology, Bharti Vidyapeeth Deemed University Medical College, Pune 411043, India
1 shared publication
Latest Publications
- 22 September 2026
- Published by Springer Nature in Indian Journal of Microbiology
- p. 1-20
Bacillus licheniformis as a Novel Therapeutic Approach for Huntington’s Disease in Caenorhabditis elegans
- 22 September 2026
- Published by Springer Nature in Indian Journal of Microbiology
- p. 1-20
Bacillus licheniformis as a Novel Therapeutic Approach for Huntington’s Disease in Caenorhabditis elegans
- Open Access
- 21 November 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (12) , 653
High-Throughput 3D Bioprinted Organoids of Skin Cancer Utilized for Diagnosis and Personalized Therapy
Recent advancements in three-dimensional (3D) bioprinting have revolutionized the modeling of skin cancer, enabling the fabrication of high-throughput, patient-specific organoids that recapitulate the structural, functional, and microenvironmental complexity of native tumors. This review focuses on the integration of cutting-edge bioprinting technologies with bioengineered extracellular matrices and patient-derived cells to generate physiologically relevant skin cancer models for diagnostic and personalized medicine applications. Key technological innovations, including novel bioinks, multi-material printing strategies, and biomimetic approaches, are discussed for their ability to replicate tumor-stroma interactions, vascularization, and immune microenvironments. The utility of bioprinted organoids in high-throughput drug screening, mutation-targeted therapy design, and biomarker discovery is critically evaluated. Additionally, we address current challenges in standardization, reproducibility, and clinical translation, highlighting regulatory and quality-control considerations. Collectively, this review emphasizes the transformative potential of 3D bioprinted skin cancer organoids as platforms for precision oncology, bridging bioengineering advances with translational research to accelerate therapeutic development and personalized treatment strategies.
- 21 November 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (12) , 653
Open AccessHigh-Throughput 3D Bioprinted Organoids of Skin Cancer Utilized for Diagnosis and Personalized Therapy
Recent advancements in three-dimensional (3D) bioprinting have revolutionized the modeling of skin cancer, enabling the fabrication of high-throughput, patient-specific organoids that recapitulate the structural, functional, and microenvironmental complexity of native tumors. This review focuses on the integration of cutting-edge bioprinting technologies with bioengineered extracellular matrices and patient-derived cells to generate physiologically relevant skin cancer models for diagnostic and personalized medicine applications. Key technological innovations, including novel bioinks, multi-material printing strategies, and biomimetic approaches, are discussed for their ability to replicate tumor-stroma interactions, vascularization, and immune microenvironments. The utility of bioprinted organoids in high-throughput drug screening, mutation-targeted therapy design, and biomarker discovery is critically evaluated. Additionally, we address current challenges in standardization, reproducibility, and clinical translation, highlighting regulatory and quality-control considerations. Collectively, this review emphasizes the transformative potential of 3D bioprinted skin cancer organoids as platforms for precision oncology, bridging bioengineering advances with translational research to accelerate therapeutic development and personalized treatment strategies.
- Open Access
Integrating 3D Bioprinting with Organoid Technology-Based Breast Cancer Models for Drug Evaluation
Breast cancer remains one of the leading causes of cancer morbidity and mortality among women worldwide. Conventional two-dimensional (2D) cell culture models and animal studies often fail to accurately recapitulate the complex tumor microenvironment and heterogeneous nature of breast cancer. Recent advancements in tissue engineering have enabled the development of more physiologically relevant models using three-dimensional (3D) bioprinting and organoid technology. This study focuses on integrating 3D bioprinting with patient-derived organoid models to replicate breast cancer tissue architecture, cellular heterogeneity, and tumor-stroma interactions. Utilizing biomimetic bioinks and customized bioprinting protocols, we successfully fabricated breast cancer tissue constructs embedded with stromal and immune components. These engineered models demonstrated high fidelity in mimicking in vivo tumor pathophysiology, including angiogenesis, epithelial–mesenchymal transition, and extracellular matrix remodeling. Furthermore, the platform allowed for high-throughput drug screening and evaluation of therapeutic responses, revealing differential sensitivities to chemotherapeutics and targeted therapies. Our findings highlight the potential of bioprinted organoid models as powerful tools for personalized medicine, enabling more predictive and reliable cancer research and drug development.
Open AccessIntegrating 3D Bioprinting with Organoid Technology-Based Breast Cancer Models for Drug Evaluation
Breast cancer remains one of the leading causes of cancer morbidity and mortality among women worldwide. Conventional two-dimensional (2D) cell culture models and animal studies often fail to accurately recapitulate the complex tumor microenvironment and heterogeneous nature of breast cancer. Recent advancements in tissue engineering have enabled the development of more physiologically relevant models using three-dimensional (3D) bioprinting and organoid technology. This study focuses on integrating 3D bioprinting with patient-derived organoid models to replicate breast cancer tissue architecture, cellular heterogeneity, and tumor-stroma interactions. Utilizing biomimetic bioinks and customized bioprinting protocols, we successfully fabricated breast cancer tissue constructs embedded with stromal and immune components. These engineered models demonstrated high fidelity in mimicking in vivo tumor pathophysiology, including angiogenesis, epithelial–mesenchymal transition, and extracellular matrix remodeling. Furthermore, the platform allowed for high-throughput drug screening and evaluation of therapeutic responses, revealing differential sensitivities to chemotherapeutics and targeted therapies. Our findings highlight the potential of bioprinted organoid models as powerful tools for personalized medicine, enabling more predictive and reliable cancer research and drug development.